This is my fourth collection of biopharma haiku. I hope you enjoy them!
Medical update
Theranos now a zombie
Not dead or alive
Shkreli fraud trial
“Misunderstood genius” or
Liar, cheat, and thief?
FDA good news
“Yelp for drugs” will not happen
Moronic idea
The BCRA
Will McConnell find the votes?
When hell freezes over
Best Trump decision
Keep Collins at NIH
Widely respected
CAR-T therapy
BCMA data strong
Great news in MM
Amgen – Thousand Oaks
Law firm or drug company?
The debate rages on
Theranos lingers
Unicorn turns to sick frog
Investors sad, broke
Drug pricing reform
Trump talks big yet does nothing
Just another lie
Combo therapies
Embraced by biopharma
Some should work out well
Big unsolved problem:
Reproducibility
Not going away
Drug prices sky high
Some curb yearly increases
Most not on board yet
EpiPen storm grows
Mylan ripped off Medicade
Pockets huge profits
New York fraud trial
Will Shkreli go to prison?
Wu Tang Clan laughing
Biosimilars
Winning approval big time
Market share captured?
The March for Science
Accomplished what exactly?
Only time will tell
Reimportation
Get our drugs from Canada
Pocket big savings
Sweeping the nation
Opioid epidemic
How many will die?
Scott Gottlieb arrives
New FDA leadership
Expecting good things
An FDA first
Opana ER takedown
Move will help save lives
Slowly progressing
Personalized Medicine
Seen as a great hope
IPO window
Some biotechs sailed right through
Others crashed into
IO combos thrive
Keytruda and Opdivo
Hundreds of trials
Keytruda approved
Hits mutations, not organs
A new paradigm
Nobody knew that
Healthcare was complicated?
Wrong! Everyone knew!
Republicans push
BCRA disaster
Poor will lose healthcare
Cut off Medicaid?
Pre-existing conditions
Uninsurable
Not hard to predict
Emergency rooms jam-packed
Where else will poor go?
CRISPR targeting
Does it hit off target sites?
No conclusions yet
Taken off market
First gene therapy was pulled
Just did not sell well
Repatriation
Big piles overseas money
Can pharma reclaim?
Alexion woes
Leadership swept out the door
Are problems fixed now?
Valeant troubles
Profits dropping, debt load high
Stockholder nightmare
Good news for patients
FDA approvals up
Banner year for drugs
New FDA chief
Pharma, BIO support him
Expectations high
Whopping healthcare costs
Drugs, PBMs, insurers
All must share the blame
What drives high prices?
Players take outsized profits
Greed drives costs upward
China biotech
Starting to show real progress
Red dragon rising
Generic drug costs
FDA speeds approval
Three will get it done
Moderna value
Fund managers wrote it down
Unicorn hit hard
Many skeptics think
Sarepta DMD drug
Simply placebo
Support very weak
Republican health care bill
Passage equals death
Doctors not aware
Overlapping surgeries
Puts patients at risk?
Cancer survivors
Helpful to share your stories
Gives hope to others